Article

Top FDA Drug Approvals of 2016

Author(s):

Laurie Toich, Assistant Editor

This year's top drug approvals.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
1 expert is featured in this series.
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
5 experts in this video
5 experts in this video
Related Content
Op-Ed: Expand Patient Choice to Lower Medication Costs
June 6th 2025

Op-Ed: Expand Patient Choice to Lower Medication Costs

Colin Edgerton, MD
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Macular degeneration is a medical condition which may result in blurred or no vision in the center of the visual field - Image credit: Tunatura | stock.adobe.com
June 6th 2025

GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes

Kennedy Ferruggia, Assistant Editor
New Programs Aim to Improve Implementation of Cardiovascular Interventions
June 3rd 2025

New Programs Aim to Improve Implementation of Cardiovascular Interventions

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Op-Ed: Prescribing Cascade Is Avoidable—If We Empower Pharmacists to Intervene
June 6th 2025

Op-Ed: Prescribing Cascade Is Avoidable—If We Empower Pharmacists to Intervene

Danielle Joset, PharmD, BCACP, MHA
Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
June 6th 2025

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Gillian McGovern, Associate Editor